Johnson & Johnson (NYSE:JNJ) is a global healthcare company known for its pharmaceuticals, medical devices, and consumer health products. On December 2, 2025, Barclays set a price target of $197 for JNJ, while the stock was trading at $205.34. This suggests a potential downside of about -4.06% from the target price. Currently, JNJ is priced at $205.34, reflecting a decrease of approximately 0.76% with a change of -$1.58. The stock has fluctuated between a low of $205.34 and a high of $207.67 today. Over the ...

Key Takeaways JNJ secured EU approval for Imaavy as an add-on therapy for generalized myasthenia gravis.Phase III and II/III studies showed Imaavy plus standard care delivered sustained disease control.Imaavy was approved in the United States in April 2025 for treating generalized myasthenia gravis.Johnson & Johnson (JNJ) announced that the European Commission has approved Imaavy (nipocalimab) as an add-on therapy for the treatment of generalized myasthenia gravis (gMG) in adults and adolescents.The targete ...